Related Experiment Video
Updated: Jun 7, 2026
Novel RNA-Binding Proteins Isolation by the RaPID Methodology
Published on: September 30, 2016
Identification, prioritization, and evaluation of RlpA protein as a target against multidrug-resistant Pseudomonas
Mansour K Gatasheh1, Nandagopal Murugan2, Rajapandiyan Krishnamoorthy3
1Department of Biochemistry, College of Science, King Saud University, P.O.Box 2455, Riyadh, 11451, Saudi Arabia.
Abstract:
According to the World Health Organization, infectious diseases, particularly those caused by multidrug-resistant bacteria (MDR), are projected to claim the lives of 15 million people by 2050. Septicemia carries a higher morbidity and mortality rate than infections caused by susceptible Pseudomonas aeruginosa, and MDR-mediated ocular infections can lead to impaired vision and blindness. To identify and develop a potential drug against MDR P. aeruginosa, we employed in silico reverse genetics-based target mining, drug prioritization, and evaluation. Rare Lipoprotein A (RlpA) was selected as the target protein, and its crystal structure was geometrically optimized. Molecular docking and virtual screening analyses revealed that RlpA exhibits strong binding affinity with 11 compounds. Among these, 3-chlorophthalic acid was evaluated, and subsequent in vitro assays demonstrated significant anti-Pseudomonas activity with negligible cytotoxicity. The compound was further evaluated against both drug-susceptible and MDR P. aeruginosa strains in vitro, with cytotoxicity assessed using an MTT assay. The study demonstrated that 3-chlorophthalic acid exhibits potent anti-Pseudomonas activity with minimal toxicity to host cells. Consequently, this compound emerges as a promising candidate against MDR P. aeruginosa, warranting further investigation.
Insights
Multidrug-resistant Pseudomonas aeruginosa infections pose a significant threat. Researchers identified 3-chlorophthalic acid as a potent drug candidate, showing strong anti-Pseudomonas activity with minimal host cell toxicity.
Area of Science:
- Microbiology
- Drug Discovery
- Computational Biology
Background:
- Multidrug-resistant (MDR) bacteria, including Pseudomonas aeruginosa, represent a growing global health crisis, projected to cause 15 million deaths by 2050.
- MDR P. aeruginosa infections, particularly septicemia and ocular infections, are associated with high morbidity and mortality rates, potentially leading to blindness.
Purpose of the Study:
- To identify and develop a novel therapeutic agent targeting MDR P. aeruginosa using in silico methods.
- To evaluate the efficacy and safety of a potential drug candidate against MDR P. aeruginosa.
Main Methods:
- In silico reverse genetics-based target mining was employed to identify a suitable protein target.
- Molecular docking and virtual screening were used to identify potential drug compounds binding to the target protein, Rare Lipoprotein A (RlpA).
- In vitro assays, including MTT assay for cytotoxicity, were performed to evaluate the anti-Pseudomonas activity of the selected compound, 3-chlorophthalic acid.
Main Results:
- Rare Lipoprotein A (RlpA) was identified as a promising drug target.
- Molecular docking revealed 11 compounds with strong binding affinity to RlpA, with 3-chlorophthalic acid showing significant potential.
- In vitro studies confirmed that 3-chlorophthalic acid exhibits potent activity against both drug-susceptible and MDR P. aeruginosa strains with negligible cytotoxicity.
Conclusions:
- 3-chlorophthalic acid demonstrates significant anti-Pseudomonas activity and low host cell toxicity.
- This compound is a promising candidate for further development as a therapeutic agent against MDR P. aeruginosa infections.
- The study highlights the potential of in silico approaches in accelerating the discovery of novel antimicrobial agents.
